Syndax Pharmaceuticals, Inc. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
Syndax Pharmaceuticals, Inc. (SNDX) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $92.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2022-05-09
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2022-03-31 was $92.00K, a 16.46% increase year-over-year.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2021-09-30 was $99.00K, a 5.32% increase year-over-year.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2021-06-30 was $64.00K, a 24.71% decline year-over-year.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2021-03-31 was $79.00K, a 23.44% increase year-over-year.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2021 was $367.00K, a 6.38% increase from fiscal 2020.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2020 was $345.00K, a 89.56% increase from fiscal 2019.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2019 was $182.00K, a 8.08% decline from fiscal 2018.
- Syndax Pharmaceuticals, Inc. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2018 was $198.00K, a 104.12% increase from fiscal 2017.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|---|---|---|
| 2022-03-31 | $92.00K 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $367.00K 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $99.00K 10-Q · filed 2021-11-15 | $163.00K derived: sum of 2 quarters · filed 2021-11-15 | $242.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2021-06-30 | $64.00K 10-Q · filed 2021-11-15 | $143.00K derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2021-03-31 | $79.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $345.00K 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $94.00K 10-Q · filed 2021-11-15 | $179.00K derived: sum of 2 quarters · filed 2021-11-15 | $243.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $85.00K 10-Q · filed 2021-11-15 | $149.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $64.00K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $182.00K 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $53.00K 10-Q · filed 2020-11-05 | $99.00K derived: sum of 2 quarters · filed 2020-11-05 | $125.00K derived: sum of 3 quarters · filed 2020-11-05 | $194.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $46.00K 10-Q · filed 2020-11-05 | $72.00K derived: sum of 2 quarters · filed 2020-11-05 | $141.00K derived: sum of 3 quarters · filed 2021-03-12 | $173.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $26.00K 10-Q · filed 2020-11-05 | $95.00K derived: sum of 2 quarters · filed 2021-03-12 | $127.00K derived: sum of 3 quarters · filed 2021-03-12 | $190.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $101.00K derived: sum of 2 quarters · filed 2021-03-12 | $164.00K derived: sum of 3 quarters · filed 2021-03-12 | $198.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | $32.00K 10-Q · filed 2019-11-07 | $95.00K derived: sum of 2 quarters · filed 2019-11-07 | $129.00K 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $63.00K 10-Q · filed 2019-11-07 | $97.00K 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | $34.00K 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $97.00K 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |